DB:LTIA

Stock Analysis Report

Executive Summary

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Aptose Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LTIA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.6%

LTIA

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

232.3%

LTIA

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: LTIA exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: LTIA exceeded the German Market which returned -17.7% over the past year.


Shareholder returns

LTIAIndustryMarket
7 Day16.6%11.2%7.3%
30 Day-19.6%-5.3%-17.9%
90 Day18.1%-21.9%-25.8%
1 Year232.3%232.3%-4.9%-5.1%-15.1%-17.7%
3 Year489.8%489.8%17.7%16.5%-18.7%-25.6%
5 Year11.8%11.8%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Aptose Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aptose Biosciences undervalued compared to its fair value and its price relative to the market?

4.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LTIA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LTIA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LTIA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LTIA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LTIA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LTIA is overvalued based on its PB Ratio (4.8x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Aptose Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

18.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LTIA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LTIA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LTIA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if LTIA's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if LTIA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LTIA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aptose Biosciences performed over the past 5 years?

-22.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LTIA is currently unprofitable.

Growing Profit Margin: LTIA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LTIA is unprofitable, and losses have increased over the past 5 years at a rate of -22.2% per year.

Accelerating Growth: Unable to compare LTIA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LTIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: LTIA has a negative Return on Equity (-27.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aptose Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: LTIA's short term assets ($98.8M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: LTIA's short term assets ($98.8M) exceed its long term liabilities ($1.0M).


Debt to Equity History and Analysis

Debt Level: LTIA is debt free.

Reducing Debt: LTIA has no debt compared to 5 years ago when its debt to equity ratio was 1.4%.


Balance Sheet

Inventory Level: LTIA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LTIA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LTIA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LTIA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -20.4% each year.


Next Steps

Dividend

What is Aptose Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LTIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LTIA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LTIA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LTIA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LTIA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

William Rice (60yo)

6.42s

Tenure

US$2,499,486

Compensation

Dr. William G. Rice, Ph.D., has been the Chief Executive Officer and President of Aptose Biosciences Inc. since October 28, 2013. Dr. Rice served as the President and Chief Executive Officer of Cylene Phar ...


CEO Compensation Analysis

Compensation vs Market: William's total compensation ($USD2.50M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: William's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
William Rice
Chairman6.42yrsUS$2.50m0.22% $896.9k
Gregory Chow
Executive VP6.25yrsUS$1.79m0.18% $725.0k
Daniel Von Hoff
Senior VP of Medical Affairsno datano datano data
Jotin Marango
Senior VP & Chief Business Officer0.75yrno data0.052% $215.6k
Rafael Bejar
Senior VP & Chief Medical Officer0.17yrno datano data

6.3yrs

Average Tenure

47yo

Average Age

Experienced Management: LTIA's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Rice
Chairman6.42yrsUS$2.50m0.22% $896.9k
Daniel Von Hoff
Senior VP of Medical Affairsno datano datano data
Mark Vincent
Independent Director12.5yrsUS$173.71k0.0085% $35.0k
Denis Burger
Lead Independent Directorno dataUS$221.71k0.021% $87.6k
Erich Platzer
Independent Director5.25yrsUS$169.71k0.18% $727.6k
Warren Whitehead
Independent Director8.92yrsUS$173.71k0.066% $269.5k
Caroline Loewy
Independent Director1.92yrsUS$99.34kno data
Brian Druker
Chairman of Scientific Advisory Board6.42yrsno datano data
Michael Andreeff
Member of Scientific Advisory Board5yrsno datano data
Carol Ashe
Independent Director1.58yrsUS$83.28kno data

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: LTIA's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LTIA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.


Top Shareholders

Company Information

Aptose Biosciences Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptose Biosciences Inc.
  • Ticker: LTIA
  • Exchange: DB
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$641.429m
  • Listing Market Cap: CA$411.054m
  • Shares outstanding: 76.27m
  • Website: https://www.aptose.com

Number of Employees


Location

  • Aptose Biosciences Inc.
  • 12770 High Bluff Drive
  • Suite 120
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APTONasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJul 2007
APSTSX (The Toronto Stock Exchange)YesCommon SharesCACADJul 2007
LTIADB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2007
0UI8LSE (London Stock Exchange)YesCommon SharesGBCADJul 2007

Biography

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:23
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.